ストックスクリーナーアプリを入手
158.15
2.75%
4.23
アフターアワーズ：
162.00
3.85
+2.43%
前日終値:
$153.92
開ける：
$153.92
24時間の取引高:
409.72K
Relative Volume:
0.87
時価総額：
$9.51B
収益：
$354.82M
当期純損益:
$-462.76M
株価収益率:
-19.51
EPS:
-8.105
ネットキャッシュフロー:
$-460.07M
1週間 パフォーマンス:
+14.73%
1か月 パフォーマンス:
+3.38%
6か月 パフォーマンス:
+21.36%
1年 パフォーマンス:
+11.77%
1日の値動き範囲:
$152.07
$159.56
1週間の範囲:
$132.52
$159.56
52週間の値動き範囲:
$111.09
$169.37
Ascendis Pharma A S Adr Stock (ASND) Company Profile
ASND を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S Adr
|
158.15 | 9.51B | 354.82M | -462.76M | -460.07M | -8.105 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.59 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.14 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-07 | 開始されました | UBS | Buy |
| 2024-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-06-25 | アップグレード | TD Cowen | Hold → Buy |
| 2024-05-31 | 開始されました | Stifel | Buy |
| 2023-12-20 | 開始されました | Jefferies | Buy |
| 2023-06-14 | 再開されました | Credit Suisse | Neutral |
| 2023-04-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-04-04 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 開始されました | Goldman | Buy |
| 2022-08-30 | 再開されました | Berenberg | Buy |
| 2022-03-28 | 再開されました | Wedbush | Outperform |
| 2022-03-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 開始されました | Cowen | Market Perform |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-10-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-03-30 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 再開されました | Stifel | Buy |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-03-20 | 開始されました | Oppenheimer | Outperform |
| 2019-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2019-03-25 | 開始されました | Evercore ISI | Outperform |
| 2019-01-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-01-24 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 開始されました | Stifel | Buy |
| 2018-04-02 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-05-11 | 開始されました | JP Morgan | Overweight |
| 2017-03-09 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 開始されました | Credit Suisse | Outperform |
| 2016-09-26 | 開始されました | Wedbush | Outperform |
すべてを表示
Ascendis Pharma A S Adr (ASND) 最新ニュース
Dynavax Technologies Gets Relative Strength Rating Upgrade - Inkl
Novartis ADR Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Inkl
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Jump To 87 - Investor's Business Daily
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Autohome ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Inkl
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView
Ascendis Pharma A/S Sponsored ADR to Host Earnings Call - ACCESS Newswire
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView
Ascendis Pharma at TD Cowen Conference: Strategic Growth in Rare Diseases - Investing.com
Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com
Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com
Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga
Stocks To Watch: Kontoor Brands Sees RS Rating Rise To 84 - Inkl
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 82 - Investor's Business Daily
Stocks To Watch: Pony AI ADR Sees RS Rating Jump To 92 - Inkl
Ascendis Pharma's SWOT analysis: promising pipeline fuels stock potential - Investing.com
ASND’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise - Investing.com
Ascendis Pharma launches $25 million share buyback - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
Cantor Fitzgerald maintains Ascendis Pharma Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Ascendis Pharma Overweight rating - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - MSN
JPMorgan raises Ascendis Pharma target to $167, keeps Overweight - Investing.com
Ascendis Pharma A/S (ASND) Expected to Announce Earnings on Wednesday - Defense World
Goldman Sachs retains Buy on Ascendis Pharma shares, cites legal action - Investing.com
BioMarin sues Ascendis Pharma over patent infringement - Investing.com
Ascendis Pharma stock falls on missed Skytrofa revenue forecast - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - MSN
European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN
UBS starts Ascendis Pharma stock at Buy, optimistic on upcoming launches - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN
Ascendis Pharma's SWOT analysis: stock poised for growth amid challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN
Ascendis Pharma target raised to $194 on positive trial results - Investing.com
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading - MSN
Ascendis Pharma's SWOT analysis: stock faces growth hurdles amid pipeline promise - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN
European Equities Traded in the US as American Depositary Move Higher in Monday Trading - MSN
TD Cowen boosts Ascendis stock target, sees Q3 Skytrofa growth lagging but long-term outlook intact - Investing.com
Ascendis Pharma A/S ADR’s Banking’s 100-Day Moving Average at 134.03: Will the Stock Break Through? - The InvestChronicle
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 83 RS Rating - Investor's Business Daily
Ascendis reports positive 3-year hypoparathyroidism trial data - Investing.com
Ascendis Pharma launches $300 million public offering - Investing.com
Ascendis Pharma A S Adr (ASND) 財務データ
収益
当期純利益
現金流量
EPS
0.21%
1.22%
大文字化:
|
ボリューム (24 時間):